mutations and complicated kar yotype. It follows a linear evolution within the CLL clone through the recurrent acquisition of CDKN2A??? "???????????????????????????????????????????????"Duvelisib was the next PI3K inhibitor accepted from the FDA, also based on a section III randomized trial.a hundred thirty The efficacy and basic safety profile in t